Trial Profile
An observational study of tasimelteon [HETLIOZ] in patients with Smith-Magenis Syndrome
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Feb 2015
Price :
$35
*
At a glance
- Drugs Tasimelteon (Primary)
- Indications Developmental disabilities; Sleep disorders
- Focus Therapeutic Use
- 26 Feb 2015 New trial record
- 19 Feb 2015 According to media release, results of this trial are expected in first half of 2015.